Vitamin D and Stroke
1 other identifier
observational
50
1 country
1
Brief Summary
Stroke remains one of the most devastating neurological diseases, often causing death, or gross physical impairment. It is the second most common cause of death worldwide and a major cause of acquired disability in adults.Vitamin D deficiency has been reported to contribute to the risk of cardiovascular disease especially stroke.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2016
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2016
CompletedFirst Submitted
Initial submission to the registry
September 17, 2016
CompletedFirst Posted
Study publicly available on registry
September 27, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 2, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
January 3, 2017
CompletedJuly 13, 2018
July 1, 2018
4 months
September 17, 2016
July 12, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
serum 25 (OH) D levels
serum 25 (OH) D levels
Within the first 24 hours
Secondary Outcomes (4)
Stroke severity
Within the first 24 hours
Stroke etiology
Within the first 24 hours
Stroke risk factors
Within the first 24 hours
Stroke subtypes
Within the first 24 hours
Study Arms (2)
Group 1 (hemorrhagic stroke)
All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.
Group 2 (Ischemic stroke)
All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.
Interventions
It is to examine the relationship between serum 25 (OH) D levels and Stroke either ischemic or hemorrhagic types
Eligibility Criteria
patients with first -ever acute onset stroke within seven days
You may qualify if:
- Onset is within one week
- Confirmed stroke by brain CAT and / or MRI scan either haemorrhage or infarction
You may not qualify if:
- Cognitive and mental changes
- Recurrent stroke
- Hepatic and renal impairment
- Endocrinal diseases
- Steroid therapy
- Vitamin D or Ca supplementation
- Previous fractures
- Bone diseases
- brain neoplasm,
- Autoimmune diseases
- History of acute and chronic inflammatory diseases
- Malignancy,
- Trauma
- Surgery
- Acute vascular diseases that occurred within four weeks prior the onset of stroke
- +1 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Faculty of Medicine
Asyut, 74111, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
sayed abd elshafy, MD
associate professor of anesthesia and critical care
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor (Anesthesiology and Critical Care)- College of Medicine-Assiut University
Study Record Dates
First Submitted
September 17, 2016
First Posted
September 27, 2016
Study Start
September 1, 2016
Primary Completion
January 2, 2017
Study Completion
January 3, 2017
Last Updated
July 13, 2018
Record last verified: 2018-07